Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28104164 | 0.99 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL23258348 | 0.92 | PDE3A (0.56) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL582792 | 0.90 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL350552 | 0.90 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27966727 | 0.89 | PDE3A (0.54) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL28213460 | 0.87 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL30514296 | 0.85 | LMNA (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL30514303 | 0.84 | LMNA (0.50) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL366599 | 0.84 | LMNA (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL22631542 | 0.84 | LMNA (0.52) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116333019-B | Fluorocytidine compound and preparation method and application thereof | 沈阳农业大学 | 2024-04-02 | — | — | CN | claimed |
| WO-2023150622-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF CORONAVIRUS (COV) VIRAL GENOMES, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-08-10 | — | — | WO | claimed |
| CN-116333019-A | Fluorocytidine compound and preparation method and application thereof | 沈阳农业大学 | 2023-06-27 | — | — | CN | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190292540-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | UNIV MASSACHUSETTS (US) | 2019-09-26 | — | — | US | claimed |
| US-20170096664-A1 | SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-06 | — | — | US | claimed |
| US-9260760-B2 | Method for determining complete response to anticancer therapy | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-02-16 | — | — | US | claimed |
| US-20150152504-A1 | METHOD FOR DETERMINING COMPLETE RESPONSE TO ANTICANCER THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-06-04 | — | — | US | claimed |
| US-8889645-B2 | Nucleic acid modulators of glycoprotein VI | REGADO BIOSCIENCES, INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-20140128587-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | REGADO BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | claimed |
| EP-0504279-B1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORP (US) | 1997-07-09 | — | — | EP | claimed |
| US-5476932-A | Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1995-12-19 | — | — | US | claimed |
| US-5453497-A | Process for producing N4 -acyl-5'-deoxy-5-fluorocytidine compounds | HOFFMANN-LA ROCHE INC. (US) | 1995-09-26 | — | — | US | claimed |
| EP-0637966-A1 | BYSTANDER EFFECT TUMORICIDAL THERAPY. | US HEALTH (US) | 1995-02-15 | — | — | EP | claimed |
| WO-1993021959-A1 | BYSTANDER EFFECT TUMORICIDAL THERAPY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-11-11 | — | — | WO | claimed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | claimed |
| EP-0504279-A4 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | — | 1993-02-17 | — | — | EP | claimed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | claimed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | claimed |
| CN-1045791-A | Use the cooperative compositions HIV inhibiting of nucleoside derivates | ONCOGEN (US) | 1990-10-03 | — | — | CN | claimed |